Multicentre clinical trials of benzimidazole-carbamates in human cystic echinococcosis (phase 2).
A multicentre study which constituted the second phase of trials of the efficacy of albendazole and mebendazole in human cystic echinococcosis was coordinated by WHO. A total of 112 patients from four clinical centres in Beirut, Paris, Rome and Sofia completed standardized dosage of regimens of each drug and 68 patients were followed up for at least 12 months after treatment. Albendazole was more effective than mebendazole and adverse reactions were comparable with both treatment regimens. At least 12 months is needed after treatment for an objective evaluation of the efficacy of benzimidazoles. At present, treatment with albendazole or mebendazole should be reserved for inoperable cases of cystic echinococcosis (under strict medical supervision) and individualized according to the patient's response and the occurrence and severity of adverse reactions.
Davis
A
A
Dixon
H
H
Pawlowski
Z S
ZS
D000293:Adolescent; D000328:Adult; D000368:Aged; D001562:Benzimidazoles / Q000009:adverse effects / Q000592:standards / Q000627:therapeutic use*; D002219:Carbamates / Q000009:adverse effects / Q000592:standards / Q000627:therapeutic use*; D002648:Child; D004443:Echinococcosis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D014944:World Health Organization
D001562:Benzimidazoles; D002219:Carbamates